Cécile Badoual

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2942377/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer. Cancer Research, 2013, 73, 128-138.	0.9	554
2	Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers. Clinical Cancer Research, 2006, 12, 465-472.	7.0	517
3	Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open, 2017, 2, e000213.	4.5	248
4	Induction of resident memory T cells enhances the efficacy of cancer vaccine. Nature Communications, 2017, 8, 15221.	12.8	231
5	Mucosal Imprinting of Vaccine-Induced CD8 ⁺ T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors. Science Translational Medicine, 2013, 5, 172ra20.	12.4	195
6	Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma. Cancer Research, 2017, 77, 1075-1082.	0.9	166
7	Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nature Communications, 2015, 6, 6044.	12.8	153
8	Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncolmmunology, 2012, 1, 326-333.	4.6	95
9	Molecular Profiling of Salivary Gland Intraductal Carcinoma Revealed a Subset of Tumors Harboring NCOA4-RET and Novel TRIM27-RET Fusions. American Journal of Surgical Pathology, 2018, 42, 1445-1455.	3.7	91
10	Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer—Just About Ready for Prime-Time?. Cancers, 2019, 11, 283.	3.7	86
11	Diagnosis of HPV-driven head and neck cancer with a single test in routine clinical practice. Modern Pathology, 2015, 28, 1518-1527.	5.5	78
12	Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer. Molecular Cancer Therapeutics, 2015, 14, 1336-1345.	4.1	77
13	The Soluble α Chain of Interleukin-15 Receptor: A Proinflammatory Molecule Associated with Tumor Progression in Head and Neck Cancer. Cancer Research, 2008, 68, 3907-3914.	0.9	75
14	Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians. Cancer Treatment Reviews, 2018, 65, 54-64.	7.7	51
15	Better understanding tumor–host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head and Neck, 2010, 32, 946-958.	2.0	50
16	Mucosal vaccines. Human Vaccines and Immunotherapeutics, 2014, 10, 2175-2187.	3.3	49
17	Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects. European Journal of Cancer, 2017, 79, 15-22.	2.8	42
18	CXCR6 deficiency impairs cancer vaccine efficacy and CD8 ⁺ resident memory T-cell recruitment in head and neck and lung tumors. , 2021, 9, e001948.		41

2

CéCILE BADOUAL

#	Article	IF	CITATIONS
19	Diagnosis of HPV driven oropharyngeal cancers: Comparing p16 based algorithms with the RNAscope HPV-test. Oral Oncology, 2016, 62, 101-108.	1.5	40
20	A prospective multicentre REFCOR study of 470 cases of head and neck Adenoid cystic carcinoma: epidemiology and prognostic factors. European Journal of Cancer, 2020, 130, 241-249.	2.8	40
21	HPV Involvement in the Tumor Microenvironment and Immune Treatment in Head and Neck Squamous Cell Carcinomas. Cancers, 2020, 12, 1060.	3.7	40
22	HPV Detection in Head and Neck Squamous Cell Carcinomas: What Is the Issue?. Frontiers in Oncology, 2020, 10, 1751.	2.8	39
23	Prospective assessment and histological analysis of adherent perinephric fat in partial nephrectomies. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 39.e9-39.e17.	1.6	37
24	Pediatric salivary gland carcinomas: Diagnostic and therapeutic management. Laryngoscope, 2017, 127, 140-147.	2.0	36
25	Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1. Modern Pathology, 2022, 35, 352-360.	5.5	33
26	Evaluation of the efficacy of the 4 tests (p16 immunochemistry, polymerase chain reaction, DNA, and) Tj ETQq0 (cohort of 348 French squamous cell carcinomas. Human Pathology, 2018, 78, 63-71.	0 rgBT /0 2.0	Overlock 10 T 31
27	Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. Oncolmmunology, 2017, 6, e1286437.	4.6	28
28	The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments. Head and Neck Pathology, 2020, 14, 330-340.	2.6	26
29	Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma. Oral Oncology, 2018, 80, 104-107.	1.5	19
30	Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Oropharynx and Nasopharynx. Head and Neck Pathology, 2022, 16, 19-30.	2.6	18
31	Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1 ⁺ Tim-3 ⁺ CD8 ⁺ T Cells. Journal of Visualized Experiments, 2018, , .	0.3	14
32	High expression of spliced X-Box Binding Protein 1 in lung tumors is associated with cancer aggressiveness and epithelial-to-mesenchymal transition. Scientific Reports, 2020, 10, 10188.	3.3	14
33	HPV RNA CISH score identifies two prognostic groups in a p16 positive oropharyngeal squamous cell carcinoma population. Modern Pathology, 2018, 31, 1645-1652.	5.5	13
34	HPV detection and genotyping of head and neck cancer biopsies by molecular testing with regard to the new oropharyngeal squamous cell carcinoma classification based on HPV status. Pathology, 2019, 51, 421-425.	0.6	12
35	Clinical assessment of the miR-34, miR-200, ZEB1 and SNAIL EMT regulation hub underlines the differential prognostic value of EMT miRs to drive mesenchymal transition and prognosis in resected NSCLC. British Journal of Cancer, 2021, 125, 1544-1551.	6.4	11
36	Juvenile-Onset Recurrent Respiratory Papillomatosis Aggressiveness: In Situ Study of the Level of Transcription of HPV E6 and E7. Cancers, 2020, 12, 2836.	3.7	9

CéCILE BADOUAL

#	Article	IF	CITATIONS
37	Prognostic value of circulating tumor cells in advanced gastroesophageal adenocarcinomas in the randomized trial PRODIGE 17- MEGA (Unicancer GI-AGEO) Journal of Clinical Oncology, 2016, 34, 4030-4030.	1.6	8
38	Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer. Gynecologic Oncology, 2022, , .	1.4	5
39	The LXCXE Retinoblastoma Protein-Binding Motif of FOG-2 Regulates Adipogenesis. Cell Reports, 2017, 21, 3524-3535.	6.4	4
40	Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis. Journal of Visualized Experiments, 2019, , .	0.3	4
41	Is sexual harassment and psychological abuse among medical students a fatality? A 2-year study in the Paris Descartes School of Medicine. Medical Teacher, 2021, 43, 1054-1062.	1.8	4
42	Hope in the Long Road Toward the Development of a Therapeutic Human Papillomavirus Vaccine. Clinical Cancer Research, 2016, 22, 2317-2319.	7.0	3
43	Mutational Diversity of Lung Cancer and Associated Lymph Nodes. An Exploratory Prospective Study of 4 Resected cIIIA-N2. Pathology and Oncology Research, 2019, 25, 319-325.	1.9	2
44	The integrity of the FOGâ€2 LXCXE pRbâ€binding motif is required for small intestine homeostasis. Experimental Physiology, 2019, 104, 1074-1089.	2.0	0
45	Prospective assessment of the adherent perinephric fat in partial nephrectomies: Predictors and impact on peri-operative outcomes Journal of Clinical Oncology, 2016, 34, 543-543.	1.6	О